广西医学
廣西醫學
엄서의학
GUANGXI MEDICAL JOURNAL
2014年
9期
1196-1198,1221
,共4页
叶新平%苏智雄%尚丽明%李佳梅%彭宁%朱广志%苏浩%覃晓%彭涛
葉新平%囌智雄%尚麗明%李佳梅%彭寧%硃廣誌%囌浩%覃曉%彭濤
협신평%소지웅%상려명%리가매%팽저%주엄지%소호%담효%팽도
肝细胞癌%非根治性切除术%索拉非尼%血管内皮生长因子
肝細胞癌%非根治性切除術%索拉非尼%血管內皮生長因子
간세포암%비근치성절제술%색랍비니%혈관내피생장인자
Hepatocellular carcinoma%Non-radical resection%Sorafenib%Vascular endothelial growth factor
目的：探讨非根治性肝切除术联合索拉非尼治疗肝细胞癌的疗效及其与肿瘤组织血管内皮生长因子（ VEGF）表达的关系。方法32例肝癌患者均行非根治性切除术，术后服用索拉非尼，观察近期疗效。采用免疫组化方法检测肝癌组织VEGF的表达，评价肝癌疗效与VEGF表达的关系。结果术后转移复发24例（75．0％），死亡12例（37．5％），存活20例；复发时间为（8．33±3．95）个月，中位总生存时间（OS）为19．5个月。癌组织中VEGF阳性表达24例（75．0％），阴性表达8例（25．0％）， VEGF阳性组与VEGF阴性组的中位OS分别为17．02和20．17个月，两组中位OS比较差异无统计学意义（P＞0．05）。24例复发组患者中VEGF阳性表达20例（83．3％），8例未复发组患者VEGF阳性表达4例（50．0％），复发组与未复发组患者的VEGF阳性率比较，差异无统计学意义（P＞0．05）。结论非根治性肝切除术联合索拉非尼治疗肝癌有一定疗效，其效果与肿瘤组织VEGF表达无关联。
目的：探討非根治性肝切除術聯閤索拉非尼治療肝細胞癌的療效及其與腫瘤組織血管內皮生長因子（ VEGF）錶達的關繫。方法32例肝癌患者均行非根治性切除術，術後服用索拉非尼，觀察近期療效。採用免疫組化方法檢測肝癌組織VEGF的錶達，評價肝癌療效與VEGF錶達的關繫。結果術後轉移複髮24例（75．0％），死亡12例（37．5％），存活20例；複髮時間為（8．33±3．95）箇月，中位總生存時間（OS）為19．5箇月。癌組織中VEGF暘性錶達24例（75．0％），陰性錶達8例（25．0％）， VEGF暘性組與VEGF陰性組的中位OS分彆為17．02和20．17箇月，兩組中位OS比較差異無統計學意義（P＞0．05）。24例複髮組患者中VEGF暘性錶達20例（83．3％），8例未複髮組患者VEGF暘性錶達4例（50．0％），複髮組與未複髮組患者的VEGF暘性率比較，差異無統計學意義（P＞0．05）。結論非根治性肝切除術聯閤索拉非尼治療肝癌有一定療效，其效果與腫瘤組織VEGF錶達無關聯。
목적：탐토비근치성간절제술연합색랍비니치료간세포암적료효급기여종류조직혈관내피생장인자（ VEGF）표체적관계。방법32례간암환자균행비근치성절제술，술후복용색랍비니，관찰근기료효。채용면역조화방법검측간암조직VEGF적표체，평개간암료효여VEGF표체적관계。결과술후전이복발24례（75．0％），사망12례（37．5％），존활20례；복발시간위（8．33±3．95）개월，중위총생존시간（OS）위19．5개월。암조직중VEGF양성표체24례（75．0％），음성표체8례（25．0％）， VEGF양성조여VEGF음성조적중위OS분별위17．02화20．17개월，량조중위OS비교차이무통계학의의（P＞0．05）。24례복발조환자중VEGF양성표체20례（83．3％），8례미복발조환자VEGF양성표체4례（50．0％），복발조여미복발조환자적VEGF양성솔비교，차이무통계학의의（P＞0．05）。결론비근치성간절제술연합색랍비니치료간암유일정료효，기효과여종류조직VEGF표체무관련。
Objective To study the efficacy of sorafenib combined with non-radical resection on the treatment of hepatocellular carcinoma (HCC),and to investigate its relationship with the expression of vascular endothelial growth factor (VEGF) in tumor tissues.Methods Thirty-two HCC patients underwent non-radical resection and were treated with sorafenib after operation.The short-term efficacy was observed .The expression of VEGF in HCC tissues was examined by using immunohistochemistry .The relationship between the expression of VEGF and efficacy on HCC was analyzed . Results There were 24 cases of postoperative metastasis and recurrence ( 75 .0%) ,12 cases died ( 37 .5%) and 20 cases survived.The recurrent time was (8.33 ±3.95)months, and the median overall survival(OS) time was 19.5 months.The positive VEGF expression was found in 24 cases(75.0%) and negative expression in 8 cases(25.0%) of HCC tissues .The median OS times of VEGF positive group and VEGF negative group were 17 .02 and 20 .17 months,respectively,with no significant difference between two groups (P>0.05).Twenty cases were VEGF positive (83.3%) in recurrent group(n=24),and 4 cases were VEGF positive(50.0%) in non-recurrent group(n=8),there was no significant difference in the positive rate of VEGF between recurrent group and non-recurrent group ( P>0 .05 ) . Conclusion Sorafenib combined with non-radical resection has certain efficacy for HCC patients .However , this efficacy doesn′t correlate with VEGF expression in HCC tissues .
